Nicotinamide Mononucleotide for patients undergoing cardiac surgery
Official title: Randomized Clinical Trial of Beta Nicotinamide Mononucleotide in Patients Undergoing Cardiac Surgery
Run by Brigham and Women's Hospital · NCT07013591 · Data updated 2026-11-12
This study tests whether taking NMN by mouth before and after heart surgery helps protect the heart and kidneys in adults at risk of complications.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | June 10, 2026 |
| Main results expected | October 1, 2028 |
| Study ends | January 1, 2029 |
| Registry record updated | September 21, 2026 |
| Trial ID | NCT07013591 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older undergoing elective isolated CABG and/or valve surgery with CPB who are at risk for postoperative complications.
✕Probably not a fit
Patients without the identified risk factors or those who do not respond to NMN may not see a benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a phase 2a, randomized, double-blind, placebo-controlled trial in adults undergoing elective cardiac surgery. Participants are assigned to two NMN dosing regimens or placebo, starting up to 7 days before surgery and continuing for several days afterward. The trial will evaluate whether NMN increases myocardial NAD+ levels and reduces markers of heart and kidney injury after surgery. The study uses a parallel-group design with three arms and aims to enroll 90 participants. Primary outcomes focus on biochemical and clinical indicators of cardiac and renal injury in the perioperative period.
Why it matters
Potential benefit: If successful, NMN could help reduce heart and kidney injury after cardiac surgery and improve recovery.
How similar studies have gone: Prior studies in related areas suggest potential cardiovascular benefits of NMN, but this specific perioperative approach is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years 2. Scheduled to undergo elective isolated CABG surgery and/or valve surgery with cardiopulmonary bypass (CPB) 3. At increased risk of postoperative complications based on ≥1 of the following: 1. Age ≥65 years 2. eGFR \<45 ml/min/1.73m2 3. Documented history of congestive heart failure or left ventricular ejection fraction (LVEF) ≤40% within 6 months before surgery 4. Diabetes mellitus 5. Proteinuria defined as urine albumin-to-creatinine ratio \>30 mg/g creatinine, urine protein-to-creatinine ratio \>0.05g/g creatinine, or 2+ or greater proteinuria on a urinalysis 6. Peripheral arterial disease 7. Anemia, defined as hemoglobin \<10 g/dl 8. Prior cardiac surgery Exclusion Criteria: 1. Any of the following laboratory abnormalities at the time of screening: 1. ALT \>3-fold the upper limit of normal 2. eGFR \<30 ml/min/1.73m2 or ESKD on dialysis 3. Hemoglobin \<8 g/dl 2. History of malabsorption 3. Active alcohol abuse or illicit substance use in the prior 6 months 4. Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter 5. Pregnant or breast-feeding 6. Unwillingness to use contraception while taking study drug and for 8 weeks after the last dose for women of reproductive age or non-sterilized male participants who are sexually active with a female partner of childbearing potential 7. Current use of niacin \>100 mg/day or NMN, nicotinamide, or nicotinamide riboside at any dose 8. Conflict with other research studies 9. Any condition which, in the judgement of the investigator, might increase the risk to the participant
Where it's running
-
Brigham and Women's Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Shalender Bhasin, MB, BS — Brigham and Women's Hosptial
- Study coordinator: Shalender Bhasin, MB,BS
- Email: sbhasin@bwh.harvard.edu
- Phone: 617-525-9150
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Impact of Fast-Track Anesthesia on Postoperative Delirium After Cardiac Surgery
This observational study tests whether fast-track anesthesia, compared with conventional care, is linked to lower rates of delirium after elective cardiac surgery in adults.
-
Sarcopenia in Patients After Cardiac Surgery
This observational study tests how common sarcopenia is after cardiac surgery and whether current care helps improve muscle mass and function.
-
Preoperative functional optimization for adults undergoing major cardiac or abdominal surgery
This study tests a four‑week prehabilitation program to improve fitness before elective major cardiac or abdominal surgery.
-
Oral Extubation Right After Cardiac Surgery
This trial tests whether waking patients and removing the breathing tube in the operating room after elective cardiac surgery helps recovery more quickly without added risk.
-
Frailty and Ultrasound-Guided Catheterization in Adult Cardiac Surgery Patients
This study tests whether frailty and ultrasound measurements taken before surgery can predict how difficult it will be to place an ultrasound-guided internal jugular venous catheter in adults undergoing elective cardiac surgery.
-
Prehabilitation before heart surgery for adults with congenital heart disease
This study is testing whether a tailored, supervised exercise program before heart surgery helps adults with congenital heart disease perform better and improve fitness.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.